Abstract
Overview
Introduction
Cancer treatment continues to undergo a paradigm shift with the inclusion of
molecular targeted therapies (MTT) into standard regimens. With this
transition, an entirely new set of clinical and commercial challenges have
emerged. This report analyzes the MTT market by examining the commercialized
and late-phase pipeline products, highlighting issues and strategic
recommendations for developers.
Scope
- Seven major pharmaceutical market sales forecasts from 2005 to 2015 for
approved molecular targeted therapies and key pipeline candidates
- Review of the current targeted therapies market, including profiles,
product-specific assumptions and events over the forecasted period
- Research and analysis of the targeted therapies pipeline with in-depth
clinical and commercial assessment of Phase III candidates, plus expert opinion
- Examination of product pipeline by phase, mode of action, indication, drug
class and developer, plus two commercial impact case studies
Report Highlights
In 2005, the MTT market was worth $7.5 billion and the forecast sales of
already marketed drugs in this class are expected to grow to $25.2 billion by
2015, at a CAGR of 12.9%. This growth will be driven mainly by
Genentech/Roche' s Rituxan, Herceptin and Avastin as well as Novartis' Gleevec,
all of which have already reached blockbuster status.
274 different pipeline MTTs have been identified. The introduction of current
late-phase candidates, including the pre-registered agents Tykerb (lapatinib;
GlaxoSmithKline) and Zolinza (vorinostat; Merck), will further increase the
market' s total value by $3.8 billion, enabling the targeted therapies market
to reach $29.1 billion in 2015.
The rise in cost of cancer treatment is unsustainable with growing
pharmacoeconomic pressures challenging healthcare payers globally. To counter
these hurdles, developers must become more effective at communicating the
value of their products. To this end, a comprehensive understanding of the
targeted therapies market and pipeline is critical.
Reasons to Purchase
- Acquire a detailed appreciation and impartial perspective of the targeted
cancer therapies market as a whole
- Consider and react to the specific events influencing the future potential
of marketed and pipeline targeted therapies
- Gain an insight into the emerging clinical, developmental and commercial
challenges and opportunities facing key developmental and marketed MTT drugs
View Cart
